Tigulixostat clinical trials
Also written LC350189.
How each study uses tigulixostat is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
9 studies that test it; most in 2019 (2)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 0
LG Chem (7) · Innovent Biologics Technology Limited (Shanghai R&D Center) (1) · LG Life Sciences (1)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test tigulixostat, phase 3 first.
- Apr 2027Tigulixostat (IBI128) vs Febuxostat in GoutPhase 3 · Innovent Biologics Technology Limited (Shanghai R&D Center)
Studies
Open first, then newest update. How each study uses tigulixostat is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- Tigulixostat (IBI128) vs Febuxostat in GoutActive, not recruitingPhase 3Innovent Biologics Technology Limited (Shanghai R&D Center)NCT07414394Written as Tigulixostat
- A Study to Assess Efficay and Safety of LC350189 Different Doses in Gout Patients With HyperuricemiaCompletedPhase 2LG ChemNCT03934099Written as LC350189 formulated capsule
- Tigulixostat, Phase 3 Study, Placebo Controlled in Gout PatientsCompletedPhase 3LG ChemNCT05586958Written as Tigulixostat
- Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout PatientsCompletedPhase 3LG ChemNCT05586971Written as Tigulixostat
- Effect of Tigulixostat on the Pharmacokinetics of TheophyllineCompletedPhase 1LG ChemNCT06189404Written as Tigulixostat
- Thorough QT (TQT) Study to Evaluate the Effect of LC350189 on Cardiac Repolarization in Healthy Male and Female SubjectsCompletedEarly Phase 1LG ChemNCT04966325Written as LC350189 200mg
- Renal PK Study of LC350189CompletedPhase 1LG ChemNCT04066712Written as LC350189 200 mg
- Mass Balance Study of [14C]LC350189 in Healthy VolunteersCompletedPhase 1LG ChemNCT04070846Written as [14C] LC350189
- Safety, Tolerability and Pharmacokinetic/Pharmacodynamic Characteristics of LC350189CompletedPhase 1LG Life SciencesNCT01361646Written as LC350189
As the comparator · 1 — what is tested is compared with tigulixostat
Codes
What other systems call tigulixostat · ClinicalTrials.gg INT018401
- UNII (FDA) WZ0PYQ6VLUTIGULIXOSTATOne source FDA
- NCI Thesaurus C179126TigulixostatOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | WZ0PYQ6VLU | TIGULIXOSTAT | One source FDA |
| NCI Thesaurus | C179126 | Tigulixostat | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.